Clinical Trial Update: Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial in China assessing the efficacy and safety of iGlarLixi versus standard of care in adults with uncontrolled Type 2 diabetes on oral age…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• iGlarLixi (insulin glargine + lixisenatide)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Type 2 Diabetes | Phase 4 | Status: NOT_YET_RECRUITING